

Special Issue

Targeting Immune Checkpoints for Cancer Therapy: Potential and Challenges

Message from the Guest Editors

This Special Issue of *Cancers* therefore welcomes new basic, translational and clinical research articles and timely reviews regarding all aspects of the potential and challenges of using immune checkpoint inhibitors in cancer therapy.

Guest Editors

Dr. Mona Kamal Saadeldin

Dr. Nicolò Eleonora

Dr. Amal Kamal Abdel-Aziz

Dr. D'Amico Paolo

Deadline for manuscript submissions

closed (10 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/144237

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)